-
2501
Hemorrhagic Spinal Schwannoma in Thoracolumbar Area with Total Paraplegia
Published 2019-01-01Get full text
Article -
2502
-
2503
AIDS-Related Non-Hodgkin's Lymphoma in the Era of Highly Active Antiretroviral Therapy
Published 2012-01-01“…Clinical trials investigating the role of allogeneic hematopoietic stem cell transplant in ARL are currently underway.…”
Get full text
Article -
2504
Cellular Plasticity in Prostate Cancer Bone Metastasis
Published 2015-01-01“…An electronic search was performed using PubMed for studies that have examined the differential expression of epithelial, mesenchymal, and stem cell markers in human PC bone metastasis tissues. …”
Get full text
Article -
2505
Effect of Age and Diabetes on the Response of Mesenchymal Progenitor Cells to Fibrin Matrices
Published 2011-01-01“…Mesenchymal stem cells are showing increasing promise in applications such as tissue engineering and cell therapy. …”
Get full text
Article -
2506
Prenatal Brain Damage in Preeclamptic Animal Model Induced by Gestational Nitric Oxide Synthase Inhibition
Published 2011-01-01Get full text
Article -
2507
-
2508
Discovering CRISPR-Cas system with self-processing pre-crRNA capability by foundation models
Published 2024-11-01Get full text
Article -
2509
Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signaling
Published 2025-01-01Get full text
Article -
2510
Nanosensor-based imaging of realtime dopamine release in neurons derived from iPSCs of patients with Parkinson's disease
Published 2025-04-01“…In this study, we applied NIRCat to elucidate DA release in human induced pluripotent stem cells (hiPSCs)-derived dopaminergic neurons from both healthy control and PD patient carrying GBA1 mutations. …”
Get full text
Article -
2511
Apoptotic Vesicles Attenuate Acute Lung Injury via CD73-Mediated Inhibition of Platelet Activation and NETosis
Published 2025-01-01“…To date, no pharmacological treatment has proven effective for ARDS. Mesenchymal stem cell-derived apoptotic vesicles (apoVs) were recently found to have excellent therapeutic potential for inflammatory diseases. …”
Get full text
Article -
2512
-
2513
Regulatory roles of RNA binding proteins in the Hippo pathway
Published 2025-01-01Get full text
Article -
2514
Characterization of Ex Vivo Expanded Oral Mucosal Epithelium Cells on Acellular Porcine Corneal Stroma for Ocular Surface Reconstruction
Published 2017-01-01“…Characterization showed that these sheets retain the morphologic and phenotypic characteristics of OMECs within differentiated cells and stem cells. The optimal transplantable sheets can prove to be particularly beneficial to both bilateral limbal stem cell deficiency and deep corneal lesions.…”
Get full text
Article -
2515
Multimodal Imaging of Neural Progenitor Cell Fate in Rodents
Published 2008-03-01“…For clinical application of stem cell–based therapies, noninvasive detection of applied stem cells is of high importance. …”
Get full text
Article -
2516
Diagnosis and Management of Atypical Chronic Myeloid Leukemia with a t(2;13)(q33;q12) Translocation
Published 2022-01-01“…Allogeneic hematopoietic stem cell transplant is likely the preferred treatment, but this can be limited by patient psychosocial support, age, concomitant medical conditions, and availability of an appropriate donor. …”
Get full text
Article -
2517
Germ Cell Proteins in Melanoma: Prognosis, Diagnosis, Treatment, and Theories on Expression
Published 2012-01-01“…There is an ever increasing recognition that within tumors there is a subpopulation of cells with stem-cell-like characteristics that play a role in driving tumorgenesis. …”
Get full text
Article -
2518
Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
Published 2013-01-01“…With intensive salvage chemotherapy and autologous stem cell transplantation, the long-term remission rate for these patients was only 30%, but more selective treatments with higher therapeutic index are needed. …”
Get full text
Article -
2519
Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III...
Published 2022-06-01“…However, this is less apparent in older, less fit patients, who are ineligible for stem cell transplant. Research is required in this patient group, taking into account frailty and aiming to improve: treatment tolerability, clinical outcomes and quality of life.Methods and analysis Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma is a national, phase III, multicentre, randomised controlled trial comparing standard (reactive) and frailty-adjusted (adaptive) induction therapy delivery with ixazomib, lenalidomide and dexamethasone (IRD), and to compare maintenance lenalidomide to lenalidomide+ixazomib, in patients with newly diagnosed multiple myeloma not suitable for stem cell transplant. …”
Get full text
Article -
2520